Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system
MNZ may be associated with CNS disorders, even if comorbidities/concomitant drugs that are potential risk factors for CNS disorders are excluded. Additionally, CZP may suppress CNS disorders.
Authors
- Yuki Enoki (ORCID: https://orcid.org/0000-0002-5934-0670)
- K Takada (ORCID: https://orcid.org/0000-0001-6684-8280)
- Kazuaki Matsumoto (ORCID: https://orcid.org/0000-0002-5462-1684)
- Koji Tanikawa
- Masaru Samura (ORCID: https://orcid.org/0000-0002-8637-1237)
- Kazuaki Taguchi (ORCID: https://orcid.org/0000-0002-3575-0448)
- Yuki Igarashi (ORCID: https://orcid.org/0009-0002-1936-910X)
Institutions
- Teikyo Heisei University (JP)
- Keio University (JP)
- Bristol General Hospital (GB)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1080/14740338.2025.2486308
- Citations
- 1
- Primary Topic
- Infectious Encephalopathies and Encephalitis
- Type
- article
- Field-Weighted Citation Impact
- 1.40